{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:09:34Z","timestamp":1778677774432,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX108-10616PI"],"award-info":[{"award-number":["NHRI-EX108-10616PI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2410-H-002 -156 -MY3"],"award-info":[{"award-number":["106-2410-H-002 -156 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.healthpol.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T11:16:33Z","timestamp":1566299793000},"page":"1221-1229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug price, dosage and safety: Real-world evidence of oral hypoglycemic agents"],"prefix":"10.1016","volume":"123","author":[{"given":"Yu-Shiuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-627X","authenticated-orcid":false,"given":"Shou-Hsia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.healthpol.2019.08.005_bib0005","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.healthpol.2016.09.006","article-title":"Policy interventions related to medicines: survey of measures taken in European countries during 2010\u20132015","volume":"120","author":"Vogler","year":"2016","journal-title":"Health Policy"},{"issue":"2","key":"10.1016\/j.healthpol.2019.08.005_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5655\/smr.v4i2.1004","article-title":"Pharmaceutical policies in European countries in response to the global financial crisis","volume":"4","author":"Vogler","year":"2011","journal-title":"Southern Med Review"},{"issue":"6","key":"10.1016\/j.healthpol.2019.08.005_bib0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/M13-2942","article-title":"Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study","volume":"161","author":"Gagne","year":"2014","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.healthpol.2019.08.005_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc07-9918","article-title":"Generic drugs","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.healthpol.2019.08.005_bib0025","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jhealeco.2011.08.006","article-title":"Does price reveal poor-quality drugs? Evidence from 17 countries","volume":"30","author":"Bate","year":"2011","journal-title":"Journal of Health Economics"},{"issue":"7","key":"10.1016\/j.healthpol.2019.08.005_bib0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/pds.3445","article-title":"Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database","volume":"22","author":"Liou","year":"2013","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"Suppl. 1","key":"10.1016\/j.healthpol.2019.08.005_bib0035","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s40258-014-0145-2","article-title":"A systematic review of physicians\u2019 and pharmacists\u2019 perspectives on generic drug use: what are the global challenges?","volume":"13","author":"Toverud","year":"2015","journal-title":"Applied Health Economics and Health Policy"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0040","first-page":"13","article-title":"What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs","author":"Dunne","year":"2015","journal-title":"BMC Medicine"},{"issue":"12","key":"10.1016\/j.healthpol.2019.08.005_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008915","article-title":"Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review","volume":"5","author":"Colgan","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6963-11-17","article-title":"Determinants of generic drug substitution in Switzerland","volume":"11","author":"Decollogny","year":"2011","journal-title":"BMC Health Services Research"},{"issue":"9","key":"10.1016\/j.healthpol.2019.08.005_bib0055","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jech-2016-208837","article-title":"Physicians are more likely than non-physicians to use brand-name drugs to treat their chronic conditions","volume":"71","author":"Carrera","year":"2017","journal-title":"Journal of Epidemiology and Community Health"},{"issue":"6","key":"10.1016\/j.healthpol.2019.08.005_bib0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/14737167.2014.946011","article-title":"Analysis of French generic medicines retail market: why the use of generic medicines is limited","volume":"14","author":"Dylst","year":"2014","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"1","key":"10.1016\/j.healthpol.2019.08.005_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/2224-3151.115849","article-title":"Generic medicines policies in the Asia Pacific region: ways forward","volume":"2","author":"Nguyen","year":"2013","journal-title":"WHO South-East Asia Journal of Public Health"},{"issue":"6","key":"10.1016\/j.healthpol.2019.08.005_bib0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40271-016-0176-x","article-title":"What do users of generic medicines think of them? A systematic review of consumers\u2019 and patients\u2019 perceptions of, and experiences with, generic medicines","volume":"9","author":"Dunne","year":"2016","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.healthpol.2019.08.005_bib0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","article-title":"Generic versus brand-name drugs used in cardiovascular diseases","volume":"31","author":"Manzoli","year":"2016","journal-title":"European Journal of Epidemiology"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijid.2018.07.025","article-title":"High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C","volume":"75","author":"Abozeid","year":"2018","journal-title":"International Journal of Infectious Diseases"},{"issue":"3","key":"10.1016\/j.healthpol.2019.08.005_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pds.4122","article-title":"Comparative analysis of the cost and effectiveness of generic and brand-name antibiotics: the case of uncomplicated urinary tract infection","volume":"26","author":"Lin","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"2","key":"10.1016\/j.healthpol.2019.08.005_bib0090","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.591","article-title":"Comparison of outcomes following a switch from a brand to an authorized versus independent generic drug","volume":"103","author":"Hansen","year":"2018","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0095","series-title":"2017\u20132018 national health insurance in Taiwan annual report","year":"2018"},{"issue":"7","key":"10.1016\/j.healthpol.2019.08.005_bib0100","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10198-016-0832-z","article-title":"Does drug price-regulation affect healthcare expenditures?","volume":"18","author":"Ben-Aharon","year":"2017","journal-title":"The European Journal of Health Economics"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40199-014-0080-7","article-title":"The evolution of Taiwan\u2019s National Health Insurance drug reimbursement scheme","volume":"23","author":"Hsu","year":"2015","journal-title":"Daru"},{"issue":"2","key":"10.1016\/j.healthpol.2019.08.005_bib0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1355819616671540","article-title":"Reimbursement changes and drug switching: are severe patients more affected?","volume":"22","author":"Cheng","year":"2017","journal-title":"Journal of Health Services Research & Policy"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0115","first-page":"234941","article-title":"Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan","volume":"2014","author":"Wang","year":"2014","journal-title":"ScientificWorld Journal"},{"issue":"Suppl. 1","key":"10.1016\/j.healthpol.2019.08.005_bib0120","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.healthpol.2019.08.005_bib0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/00325481.2016.1151326","article-title":"Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization","volume":"128","author":"Sun","year":"2016","journal-title":"Postgraduate Medicine"},{"issue":"1","key":"10.1016\/j.healthpol.2019.08.005_bib0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pds.3660","article-title":"Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment","volume":"24","author":"Calip","year":"2015","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0135","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","article-title":"Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study","volume":"346","author":"Eurich","year":"2013","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.healthpol.2019.08.005_bib0140","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jamainternmed.2014.5294","article-title":"Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study","volume":"174","author":"Berkowitz","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"19","key":"10.1016\/j.healthpol.2019.08.005_bib0145","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/heartjnl-2015-309164","article-title":"Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes","volume":"102","author":"Anyanwagu","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0150","series-title":"ATC classification index with DDDs","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2019"},{"issue":"11","key":"10.1016\/j.healthpol.2019.08.005_bib0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/pds.3506","article-title":"A review of covariate selection for non-experimental comparative effectiveness research","volume":"22","author":"Sauer","year":"2013","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0160","series-title":"Proceedings of the Twenty-Ninth Annual SAS\u00ae Users Group International Conference","article-title":"Performing a 1:N case-control match on propensity score","author":"Parsons","year":"2004"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0165","series-title":"the 13th Annual Conference of the Southeast SAS Users Group","article-title":"GLM to GLIMMIX - which model to choose?","author":"Cerrito","year":"2005"},{"issue":"4","key":"10.1016\/j.healthpol.2019.08.005_bib0170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.chest.2017.03.037","article-title":"Morphine use in the ED and outcomes of patients with acute heart failure: a propensity score-matching analysis based on the EAHFE registry","volume":"152","author":"Miro","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0175","series-title":"Equitable access to essential medicines: a framework for collective action","year":"2004"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0180","series-title":"Estimated costs of production and potential prices for the WHO Essential Medicines List","author":"Hill","year":"2019"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0185","series-title":"Trends in pricing and generic competition within the oral antibiotic drug market in the United States","author":"Alpern","year":"2019"},{"issue":"8","key":"10.1016\/j.healthpol.2019.08.005_bib0190","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1503\/cmaj.161082","article-title":"Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada","volume":"189","author":"Morgan","year":"2017","journal-title":"CMAJ"},{"issue":"11","key":"10.1016\/j.healthpol.2019.08.005_bib0195","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jval.2018.04.1826","article-title":"Predictors of drug shortages and association with generic drug prices: a retrospective cohort study","volume":"21","author":"Dave","year":"2018","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.healthpol.2019.08.005_bib0200","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/jac\/dkq093","article-title":"Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance","volume":"65","author":"Jensen","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12962-018-0092-0","article-title":"Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case","volume":"16","author":"Prada","year":"2018","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"7","key":"10.1016\/j.healthpol.2019.08.005_bib0210","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006940","article-title":"Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea","volume":"5","author":"Yoo","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0215","first-page":"127","article-title":"Effects of hospital generic drug substitution on diabetes therapy","volume":"8","author":"Chen","year":"2014","journal-title":"Patient Preference and Adherence"},{"issue":"3","key":"10.1016\/j.healthpol.2019.08.005_bib0220","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing generic drug markets in Europe and the United States: prices, volumes, and spending","volume":"95","author":"Wouters","year":"2017","journal-title":"The Milbank Quarterly."},{"issue":"1","key":"10.1016\/j.healthpol.2019.08.005_bib0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10198-010-0226-6","article-title":"Generic substitution: micro evidence from register data in Norway","volume":"12","author":"Dalen","year":"2011","journal-title":"The European Journal of Health Economics"},{"issue":"4","key":"10.1016\/j.healthpol.2019.08.005_bib0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.medmal.2011.10.013","article-title":"Generic antibiotic drugs: is effectiveness guaranteed?","volume":"42","author":"Gauzit","year":"2012","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"issue":"10","key":"10.1016\/j.healthpol.2019.08.005_bib0235","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/11585970-000000000-00000","article-title":"Does the market share of generic medicines influence the price level?: a European analysis","volume":"29","author":"Dylst","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.healthpol.2019.08.005_bib0240","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing generic drug markets in Europe and the United States: prices, volumes, and spending","volume":"95","author":"Wouters","year":"2017","journal-title":"The Milbank Quarterly"},{"key":"10.1016\/j.healthpol.2019.08.005_bib0245","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010814-124649","article-title":"The ethics and economics of pharmaceutical pricing","volume":"55","author":"Parker-Lue","year":"2015","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"8","key":"10.1016\/j.healthpol.2019.08.005_bib0250","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Yao","year":"2017","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1016\/j.healthpol.2019.08.005_bib0255","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.healthpol.2017.02.002","article-title":"Payers\u2019 experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia","volume":"121","author":"Morgan","year":"2017","journal-title":"Health Policy"},{"issue":"12","key":"10.1016\/j.healthpol.2019.08.005_bib0260","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/sim.6461","article-title":"Evaluation of multi-outcome longitudinal studies","volume":"34","author":"Jensen","year":"2015","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1016\/j.healthpol.2019.08.005_bib0265","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/aje\/kwy250","article-title":"Some desirable properties of the Bonferroni Correction: is the Bonferroni correction really so bad?","volume":"188","author":"VanderWeele","year":"2019","journal-title":"American Journal of Epidemiology"}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851019301897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851019301897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:11:26Z","timestamp":1778674286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851019301897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0168851019301897"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2019.08.005","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug price, dosage and safety: Real-world evidence of oral hypoglycemic agents","name":"articletitle","label":"Article Title"},{"value":"Health Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healthpol.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}